Connect Biopharma Holdings Statistics
Want to see CNTB full AI Analyst Report?
Connect Biopharma Holdings (CNTB) Stock Statistics & Valuation Metrics
Total Valuation
Connect Biopharma Holdings has a market cap or net worth of $45.89M. The enterprise value is $118.77M.
- Market Cap
- $45.89M
- Enterprise Value
- $118.77M
Share Statistics
Connect Biopharma Holdings has 62,974,308 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 62,974,308
- Owned by Insiders
- 21.31%
- Owned by Institutions
- 8.08%
Financial Efficiency
Connect Biopharma Holdings’s return on equity (ROE) is -1.32 and return on invested capital (ROIC) is -135.74%.
- Return on Equity (ROE)
- -1.32
- Return on Assets (ROA)
- -0.99
- Return on Invested Capital (ROIC)
- -135.74%
- Return on Capital Employed (ROCE)
- -1.37
- Revenue Per Employee
- 1,000
- Profits Per Employee
- -866.88K
- Employee Count
- 64
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Connect Biopharma Holdings is -1.39. Connect Biopharma Holdings’s PEG ratio is -0.11.
- PE Ratio
- -1.39
- PS Ratio
- 17.07
- PB Ratio
- 1.76
- Price to FCF
- -1.48
- Price to Operating Cash Flow
- -1.48
- PEG Ratio
- -0.11
Income Statement
In the last 12 months, Connect Biopharma Holdings had revenue of 64.00K and earned -55.48M in profits. Earnings per share was -1.00.
- Revenue
- 64.00K
- Gross Profit
- 64.00K
- Operating Income
- -58.07M
- Pretax Income
- -55.28M
- Net Income
- -55.48M
- EBITDA
- -54.58M
- Earnings Per Share (EPS)
- -1.00
Cash Flow
In the last 12 months, operating cash flow was -31.93M and capital expenditures 0, giving a free cash flow of -31.93M billion.
- Operating Cash Flow
- -31.93M
- Free Cash Flow
- -31.93M
- Free Cash Flow per Share
- -0.51
Dividends & Yields
Connect Biopharma Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -67.59%
- Earnings Yield
- -68.67%
Stock Price Statistics
- Beta
- -0.25
- 52-Week Price Change
- -56.14%
- 50-Day Moving Average
- 1.19
- 200-Day Moving Average
- 2.15
- Relative Strength Index (RSI)
- 29.34
- Average Volume (3m)
- 4.04M
Important Dates
Connect Biopharma Holdings upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Connect Biopharma Holdings as a current ratio of 3.74, with Debt / Equity ratio of 1.64%
- Current Ratio
- 3.74
- Quick Ratio
- 3.74
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.69
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Connect Biopharma Holdings has paid 197.00K in taxes.
- Income Tax
- 197.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Connect Biopharma Holdings EV to EBITDA ratio is -0.65, with an EV/FCF ratio of -0.65.
- EV to Sales
- 7.52
- EV to EBITDA
- -0.65
- EV to Free Cash Flow
- -0.65
- EV to Operating Cash Flow
- -0.65
Balance Sheet
Connect Biopharma Holdings has $31.49M in cash and marketable securities with $596.00K in debt, giving a net cash position of $30.89M billion.
- Cash & Marketable Securities
- $31.49M
- Total Debt
- $596.00K
- Net Cash
- $30.89M
- Net Cash Per Share
- $0.49
- Tangible Book Value Per Share
- $0.43
Margins
Gross margin is 100.00%, with operating margin of -1196.89%, and net profit margin of -1170.27%.
- Gross Margin
- 100.00%
- Operating Margin
- -1196.89%
- Pretax Margin
- -1167.12%
- Net Profit Margin
- -1170.27%
- EBITDA Margin
- -1160.59%
- EBIT Margin
- -1167.12%
Analyst Forecast
The average price target for Connect Biopharma Holdings is $6.86, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $6.86
- Price Target Upside
- 841.92% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 7
- AI Score
- 46
